{"disease":{"id":"covid-19-vaccine","name":"covid 19 vaccine"},"drugs":{"marketed":[{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"comirnaty","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, as a second booster dose administered at least 4 months after the first booster dose, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine, in individuals who received a second booster dose of a different COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Comirnaty","generic_name":"BNT162b2 (tozinameran)","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":70,"revenue":"5400","mechanism":"Comirnaty is an mRNA-based vaccine."},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older for the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older for the Moderna COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older for the Novavax COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"covid-19-vaccine","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older for the Janssen COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Covid-19 Sterilizing","generic_name":"COVID-19 Vaccine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain))","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (subcutaneous injection)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"qirv","indication_name":"COVID-19 vaccine (mRNA-based, bivalent (XBB.1.5 and original strain)) (intramuscular injection) (0.3 mL dose) (0.3 mL dose for 6-11 years of age) (0.3 mL dose for 5-11 years of age) (0.3 mL dose for 6 months-4 years of age) (0.3 mL dose for 6 months-4 years of age, 0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age) (0.2 mL dose for 6 months-4 years of age, 0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age) (0.1 mL dose for 6 months-4 years of age, 0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age) (0.05 mL dose for 6 months-4 years of age, 0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age) (0.025 mL dose for 6 months-4 years of age, 0.0125 mL dose for 6 months-4 years of age) (0.0125 mL dose for 6 months-4 years of age)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV","generic_name":"qirv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 5 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 12 years of age and older with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b6-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 prevention in individuals 6 months through 4 years of age with a history of severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b6 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b6-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a third dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fourth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a fifth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a sixth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a seventh dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as an eighth dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with COMIRNATY, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi-xbb-1-5-riv","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older, when administered as a booster dose in a series of the Pfizer-BioNTech COVID-19 Vaccine, after completion of primary vaccination with any COVID-19 vaccine, when administered at least 2 months after the completion of primary vaccination or any subsequent booster dose with any COVID-19 vaccine, and at least 2 months after administration of a prior booster dose with any COVID-19 vaccine, and when administered to individuals who have completed primary vaccination with COMIRNATY","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi XBB.1.5)/RIV","generic_name":"bnt162b2-omi-xbb-1-5-riv","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 6 months of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 5 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":88,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06199934","title":"Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":19853610,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05126992","title":"EU Secondary Data Post-Authorisation Safety Study of AZD1222","phase":"","overall_status":"COMPLETED","enrollment_count":5321930,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04801524","title":"Text-based Reminders to Promote COVID-19 Vaccinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":250000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT04800965","title":"Text-based Interventions to Promote COVID-19 Vaccinations","phase":"NA","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05586178","title":"Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake","phase":"NA","overall_status":"COMPLETED","enrollment_count":177720,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05586204","title":"Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up","phase":"NA","overall_status":"COMPLETED","enrollment_count":154977,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06646406","title":"Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate","phase":"NA","overall_status":"COMPLETED","enrollment_count":114165,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05586165","title":"Effects of Prompt to Bundle COVID-19 Booster and Flu Shot","phase":"NA","overall_status":"COMPLETED","enrollment_count":109493,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT05095844","title":"National Vaccine Adverse Event Reporting Survey and Etiology","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Neuroganics LLC","has_results":false},{"nct_id":"NCT04834869","title":"COVID-19 Vaccines Safety Tracking (CoVaST)","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Masaryk University","has_results":false},{"nct_id":"NCT04732819","title":"Improving COVID-19 Vaccine Uptake in Nursing Homes","phase":"NA","overall_status":"COMPLETED","enrollment_count":23768,"lead_sponsor_name":"Brown University","has_results":true},{"nct_id":"NCT05012943","title":"The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":19474,"lead_sponsor_name":"Vinbiocare Biotechnology Joint Stock Company","has_results":true},{"nct_id":"NCT06357650","title":"Collaborative Open Research Initiative Study (CORIS-1)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Chisquares Incorporated","has_results":false},{"nct_id":"NCT05032976","title":"Korea Comirnaty Post-marketing Surveillance","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05825651","title":"Long COVID and Its Associations With Health Outcomes in Older Adults","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":11527,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05084950","title":"Informing the Population of Their Level of Protection Against COVID-19 in Monaco: a Prospective Study (MonaVacc)","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Centre Scientifique de Monaco","has_results":false},{"nct_id":"NCT05107479","title":"Effectiveness of Interactive Voice Response for COVID-19 Vaccination Training in the Democratic Republic of the Congo","phase":"NA","overall_status":"COMPLETED","enrollment_count":8959,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT05463419","title":"A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":5860,"lead_sponsor_name":"Yisheng Biopharma (Singapore) Pte. Ltd.","has_results":false},{"nct_id":"NCT05244356","title":"Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation","phase":"NA","overall_status":"COMPLETED","enrollment_count":5784,"lead_sponsor_name":"Clinical Research Centre, Malaysia","has_results":false},{"nct_id":"NCT04805931","title":"VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4311,"lead_sponsor_name":"VA Puget Sound Health Care System","has_results":false},{"nct_id":"NCT05571657","title":"COVID-19 Booster Dose Reminder/Recall for Adolescents","phase":"NA","overall_status":"UNKNOWN","enrollment_count":4304,"lead_sponsor_name":"Marshfield Clinic Research Foundation","has_results":false},{"nct_id":"NCT05212974","title":"COVID-19 Vaccine Hesitancy Among Nurses","phase":"","overall_status":"COMPLETED","enrollment_count":4258,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05026879","title":"Adverse Events Report of Inactivated COVID-19 Vaccine","phase":"","overall_status":"COMPLETED","enrollment_count":4040,"lead_sponsor_name":"Bozyaka Training and Research Hospital","has_results":false},{"nct_id":"NCT05508477","title":"UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":4005,"lead_sponsor_name":"Dr. Soetomo General Hospital","has_results":false},{"nct_id":"NCT05621928","title":"Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study","phase":"","overall_status":"UNKNOWN","enrollment_count":3920,"lead_sponsor_name":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","has_results":false},{"nct_id":"NCT04695652","title":"A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3854,"lead_sponsor_name":"Medigen Vaccine Biologics Corp.","has_results":false},{"nct_id":"NCT04871776","title":"Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19","phase":"NA","overall_status":"COMPLETED","enrollment_count":3671,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT05254977","title":"Post Vaccination Adverse Events in Covid-19 Vaccine Recipients","phase":"","overall_status":"COMPLETED","enrollment_count":3515,"lead_sponsor_name":"Islamia University of Bahawalpur","has_results":false},{"nct_id":"NCT04871165","title":"Analysis of Immunogenicity, Safety and Efficacy of COVID-19 Vaccines in Immunosuppressed Individuals","phase":"","overall_status":"UNKNOWN","enrollment_count":3270,"lead_sponsor_name":"Vilnius University","has_results":false},{"nct_id":"NCT05373459","title":"Effect of a Third COVID-19 Booster Among Health Care Workers","phase":"","overall_status":"COMPLETED","enrollment_count":3167,"lead_sponsor_name":"Hong Kong Sanatorium & Hospital","has_results":false},{"nct_id":"NCT05298800","title":"Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Centers for Disease Control and Prevention, China","has_results":false},{"nct_id":"NCT04691908","title":"Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"Research Institute for Biological Safety Problems","has_results":false},{"nct_id":"NCT05518760","title":"COVID-19 Effectiveness Study in the Philippines","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"University of the Philippines","has_results":false},{"nct_id":"NCT04954092","title":"Study of Gam-COVID-Vac in Adolescents","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT05735769","title":"Anti-COVID-19 Vaccine Side Effects","phase":"","overall_status":"COMPLETED","enrollment_count":2797,"lead_sponsor_name":"University of Bari","has_results":false},{"nct_id":"NCT05043246","title":"Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":2300,"lead_sponsor_name":"The Second Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT04651790","title":"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2300,"lead_sponsor_name":"Pontificia Universidad Catolica de Chile","has_results":false},{"nct_id":"NCT06646744","title":"Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)","phase":"","overall_status":"COMPLETED","enrollment_count":2100,"lead_sponsor_name":"Ana Belen Rivas Paterna","has_results":false},{"nct_id":"NCT05752201","title":"ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":2014,"lead_sponsor_name":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","has_results":false},{"nct_id":"NCT05312619","title":"The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective Cohort Survey","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Dr. Daniel Cameron & Associates","has_results":false},{"nct_id":"NCT04832932","title":"The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Mebo Research, Inc.","has_results":false},{"nct_id":"NCT05007665","title":"Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"The Second Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT05493917","title":"A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT05386355","title":"Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool","phase":"NA","overall_status":"COMPLETED","enrollment_count":1934,"lead_sponsor_name":"IDeA States Pediatric Clinical Trials Network","has_results":true},{"nct_id":"NCT05228912","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","phase":"","overall_status":"COMPLETED","enrollment_count":1870,"lead_sponsor_name":"Hospital Clinica Nova","has_results":false},{"nct_id":"NCT04988048","title":"Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":1760,"lead_sponsor_name":"Ministry of Public Health, Argentina","has_results":false},{"nct_id":"NCT04542330","title":"Using BCG to Protect Senior Citizens During the COVID-19 Pandemic","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1700,"lead_sponsor_name":"Bandim Health Project","has_results":true},{"nct_id":"NCT05162482","title":"Combination Assessment Trial of COVID-19 Vaccines (COMBAT-COVID)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":1680,"lead_sponsor_name":"Aga Khan University Hospital, Pakistan","has_results":false},{"nct_id":"NCT04709003","title":"Covid-19 Vaccine Effectiveness in Healthcare Personnel in Clalit Health Services in Israel (CoVEHPI)","phase":"","overall_status":"COMPLETED","enrollment_count":1567,"lead_sponsor_name":"Clalit Health Services","has_results":false},{"nct_id":"NCT04706156","title":"Oral Side Effects of COVID-19 Vaccine","phase":"","overall_status":"UNKNOWN","enrollment_count":1540,"lead_sponsor_name":"Masaryk University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}